Off-label use of cetuximab plus sorafenib and panitumumab plus regorafenib to personalize therapy for a patient with V600E BRAF-mutant metastatic colon cancer

Sorafenib, the first agent developed to target BRAF mutant melanoma, is a multi-kinase inhibitor that was approved by the FDA for therapy of kidney and subsequently liver cancer, and is currently in clinical trials for thyroid, lung and brain cancer. Colorectal cancer with V600E BRAF mutation has sh...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
المؤلفون الرئيسيون: Al-Marrawi, Mhd Yaser, Saroya, Bikramajit Singh, Brennan, Matthew C, Yang, Zhaohai, Dykes, Thomas M, El-Deiry, Wafik S
التنسيق: Artigo
اللغة:Inglês
منشور في: Landes Bioscience 2013
الموضوعات:
Bedside to Bench Report
الوصول للمادة أونلاين:https://ncbi.nlm.nih.gov/pmc/articles/PMC3841209/
https://ncbi.nlm.nih.gov/pubmed/23792568
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/cbt.25191
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة